DR AGARWALS HEALTH CARE L AGARWALEYE NSEPHARMA

Healthcare · Medical Instruments & Supplies · India

https://www.dragarwals.co.in

Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.

Market & Price

Market Cap

₹15,345.15 Cr

Current Price

₹484.10

High / Low (52W)

₹545.70 / ₹334.05

Beta

Valuation

Stock P/E

116.37

Industry PE

37.60

Forward P/E

58.42

PEG Ratio

Book Value

₹63.76

Price to Book

7.59

P/S

7.38

EV/EBITDA

28.54

Dividend Yield

Profitability & Returns

ROCE

9.74%

ROE

8.31%

ROA

4.82%

Profit Margin

6.40%

Op Margin

15.03%

EPS (Latest Qtr)

₹1.24

EPS (TTM)

₹4.16

Balance Sheet & Liquidity

Debt/Equity

0.50

Quick Ratio

0.96

Current Ratio

1.24

Debt

₹1,066.20 Cr

Total Assets

₹3,941.75 Cr

Current Assets

₹572.97 Cr

Working Capital

₹111.49 Cr

Ownership

Promoter Holding

75.48%

Chg in Prom Hold

-0.01%

FII / Inst Holding

19.05%

Chg in FII Hold

0.95%

Financial Snapshot

Enterprise Value

₹16,257.77 Cr

Total Revenue (TTM)

₹2,080.08 Cr

EBITDA

₹569.57 Cr

Free Cash Flow

₹-37.75 Cr

Operating Cash Flow

₹518.99 Cr

Shares Outstanding

₹31.70 Cr

Gross Margin

44.44%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

26.96%

Profit 5Y

12.28%

Revenue (YoY)

22.60%

Earnings (YoY)

20.80%

PROS

Compounding revenue at 27.0% over 5 years.
Profit CAGR of 12.3% over 5 years.

CONS

Trading at a high P/E of 116.4.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AGARWALEYE DR AGARWALS HEALTH CARE L NSEPHARMA	484.10	116.37	₹15,345.15 Cr	-	9.74%	8.31%	26.96%	12.28%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	415.49 Cr	430.72 Cr	460.22 Cr	487.42 Cr	-	529.86 Cr	564.11 Cr
Cost of Revenue	-	-	167.35 Cr	179.96 Cr	178.45 Cr	196.72 Cr	196.76 Cr
Gross Profit	-	-	292.87 Cr	307.46 Cr	320.24 Cr	333.14 Cr	367.35 Cr
Operating Expenses	-	-	222.27 Cr	242.55 Cr	251.96 Cr	257.79 Cr	282.56 Cr
Operating Income	63.46 Cr	56.63 Cr	70.60 Cr	64.91 Cr	-	75.35 Cr	84.79 Cr
EBITDA	118.33 Cr	127.52 Cr	143.92 Cr	141.25 Cr	-	154.64 Cr	175.38 Cr
Interest Expense	28.40 Cr	28.35 Cr	25.01 Cr	24.70 Cr	-	21.13 Cr	22.08 Cr
Pretax Income	33.27 Cr	40.99 Cr	58.52 Cr	53.60 Cr	-	64.76 Cr	76.62 Cr
Tax Provision	11.93 Cr	12.75 Cr	15.97 Cr	15.54 Cr	-	21.13 Cr	26.66 Cr
Net Income	16.58 Cr	22.34 Cr	32.57 Cr	30.05 Cr	-	33.74 Cr	39.71 Cr
Diluted EPS	-	0.71	1.03	0.95	-	1.06	1.24

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	1,016.48 Cr	1,327.67 Cr	1,711.00 Cr	2,080.08 Cr
Cost of Revenue	-	558.55 Cr	728.57 Cr	635.37 Cr	751.89 Cr
Gross Profit	-	457.93 Cr	599.10 Cr	1,075.63 Cr	1,328.19 Cr
Operating Expenses	-	304.38 Cr	397.25 Cr	849.99 Cr	1,034.86 Cr
Operating Income	-	153.55 Cr	201.85 Cr	225.64 Cr	293.33 Cr
EBITDA	-	283.86 Cr	406.56 Cr	499.38 Cr	615.34 Cr
Interest Expense	-	71.97 Cr	95.62 Cr	108.79 Cr	90.46 Cr
Pretax Income	-	83.59 Cr	140.57 Cr	159.85 Cr	248.64 Cr
Tax Provision	-	-19.64 Cr	45.52 Cr	49.51 Cr	80.50 Cr
Net Income	-	94.10 Cr	83.06 Cr	83.46 Cr	133.19 Cr
Diluted EPS	1.19	2.98	2.63	2.78	-

Compounded Sales Growth

5 Years:	26.96%
1 Year:	22.60%

Compounded Profit Growth

5 Years:	12.28%
1 Year:	20.80%

Stock Price Performance

1 Year:	+39.49%
6 Months:	-2.18%
3 Months:	+8.57%
1 Month:	+9.64%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	1,825.17 Cr	2,752.82 Cr	3,671.57 Cr	3,941.75 Cr
Current Assets	-	310.18 Cr	758.58 Cr	794.07 Cr	572.97 Cr
Cash & Equivalents	-	126.98 Cr	111.75 Cr	103.61 Cr	90.55 Cr
Inventory	-	36.04 Cr	51.90 Cr	80.27 Cr	94.03 Cr
Receivables	-	76.33 Cr	96.81 Cr	123.56 Cr	160.91 Cr
Total Liabilities	-	1,166.10 Cr	1,373.31 Cr	1,744.75 Cr	1,822.05 Cr
Current Liabilities	-	301.31 Cr	399.80 Cr	477.76 Cr	461.48 Cr
Long Term Debt	-	305.60 Cr	309.62 Cr	157.29 Cr	133.30 Cr
Total Debt	-	857.35 Cr	966.44 Cr	960.91 Cr	1,066.20 Cr
Total Equity	-	629.56 Cr	1,339.41 Cr	1,866.59 Cr	2,025.46 Cr
Shares Outstanding	-	31.59 Cr	31.59 Cr	31.59 Cr	31.68 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	233.11 Cr	346.00 Cr	357.13 Cr	518.99 Cr
Investing Cash Flow	-	-509.08 Cr	-913.91 Cr	-750.33 Cr	-308.45 Cr
Financing Cash Flow	-	303.34 Cr	552.68 Cr	381.85 Cr	-220.39 Cr
Capital Expenditure	-	-157.80 Cr	-232.33 Cr	-320.90 Cr	-460.58 Cr
Free Cash Flow	-	75.31 Cr	113.67 Cr	36.23 Cr	58.41 Cr
Net Change in Cash	-	27.36 Cr	-15.23 Cr	-11.35 Cr	-9.85 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	45.1%	45.1%	62.9%	63.9%
Operating Margin %	-	15.1%	15.2%	13.2%	14.1%
Net Margin %	-	9.3%	6.3%	4.9%	6.4%
ROE %	-	14.9%	6.2%	4.5%	6.6%
ROCE %	-	10.1%	8.6%	7.1%	8.4%

Shareholding Pattern

Insiders

75.48%

Institutions

19.05%

Public Float

77.69%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AGARWALEYE

No recent headlines available.

AGARWALEYE · Healthcare